????? ?? ?? ? ??? ????????????? ????????????????? ???????????????????Unfit patients even have the choice of venetoclax in addition obinutuzumab (VO) as frontline therapy. This is predicated on the phase III trial that when compared VO with ClbO in aged/unfit clients.113 VO was superior when it comes to reaction charge and development-totally free s